New partnership accelerates treatments for COPD patients (Dr. Don Sin)
Vancouver, BC-A world-renowned St. Paul’s Hospital lung researcher and Canada’s national Centre for Drug Research and Development (CDRD) have teamed up to fight one of the world’s deadliest lung illnesses – Chronic Obstructive Pulmonary Disease (COPD).
Dr. Don Sin, chest physician and leading lung researcher at Providence Health Care (PHC) and the Centre for Heart Lung Innovation (HLI) at St. Paul’s Hospital, has been working for the past 10 years to discover novel biomarkers that will lead to new therapies and improve the care of patients with COPD. Dr. Sin and his research group have made breakthrough discoveries that have shed light on why some individuals develop COPD and others do not. They are now in position to identify which of these discoveries will translate into drug targets.
CDRD’s Target Validation group, led by Dr. Edie Dullaghan, has partnered with Dr. Sin to advance his research from the lab into targeted drug development, leading to innovative therapies for patients with COPD. Now a new nine month project is underway to validate and characterize a subset of specific genes related to the disease. CDRD will analyze human lung tissue samples from both COPD and non-COPD patients in a blinded study.